Epidemiology — MCQs

Epidemiology Indian Medical PG Practice Questions and MCQs

Question 1091: Which of the following is NOT a criterion for establishing a causal association?

A. Temporal association
B. Sensitivity of association (Correct Answer)
C. Consistency of association
D. Coherence of association

Explanation: ### Explanation The criteria for establishing a causal association between an exposure and a disease are defined by **Bradford Hill’s Criteria**. These criteria help distinguish between a mere statistical correlation and a true cause-and-effect relationship. **Why "Sensitivity of Association" is the correct answer:** "Sensitivity" is a measure of a diagnostic test's validity, not a criterion for causality. In the context of Bradford Hill’s criteria, the correct term is **Strength of Association** (the magnitude of the relative risk). Sensitivity does not play a role in determining whether a factor causes a disease. **Analysis of Incorrect Options:** * **Temporal Association (A):** This is the most essential criterion. It states that the exposure must precede the outcome (cause must come before the effect). * **Consistency of Association (C):** This means the findings are reproducible by different investigators, in different places, and using different study designs. * **Coherence of Association (D):** This implies that the causal interpretation should not conflict with the generally known facts of the natural history and biology of the disease. **High-Yield Facts for NEET-PG:** * **Bradford Hill’s Criteria (9 total):** Temporality (strongest), Strength, Specificity, Consistency, Biological Gradient (Dose-response), Plausibility, Coherence, Experiment, and Analogy. * **Temporality** is the only criterion that is absolutely essential to establish causality. * **Specificity** is considered the weakest criterion because many diseases (e.g., lung cancer) have multiple causes, and many causes (e.g., smoking) lead to multiple diseases. * **Biological Gradient** refers to the dose-response relationship (higher exposure leads to higher risk).

Question 1092: What is the term for the first case identified in an epidemic?

A. Index case
B. Primary case (Correct Answer)
C. First case
D. None of the above

Explanation: **Explanation:** In epidemiology, identifying the sequence of cases is crucial for understanding the spread of an outbreak. **1. Why "Primary Case" is correct:** The **Primary Case** is defined as the individual who introduces the disease into a population or community. It is the very first case to occur in an epidemic. In many instances, the primary case is identified retrospectively during an investigation. **2. Why the other options are incorrect:** * **Index Case (Option A):** This is the most common distractor. The index case is the **first case that comes to the attention of the investigator** or health authorities. It is the "starting point" of the epidemiological investigation. While the index case can sometimes be the primary case, they are often different (e.g., the primary case may have recovered or died before the investigation began). * **First Case (Option C):** This is a generic term and not a standard epidemiological definition used in textbooks like Park’s Preventive and Social Medicine. **3. High-Yield Clinical Pearls for NEET-PG:** * **Secondary Case:** These are cases that develop from contact with the primary case within the incubation period. * **Secondary Attack Rate (SAR):** This measures the spread of a disease from a primary case to susceptible contacts within a household or closed group. It is an indicator of the **communicability** of an infectious agent. * **Formula for SAR:** (Number of exposed persons developing the disease within the incubation period / Total number of exposed susceptible contacts) × 100. * **Note:** When calculating SAR, the primary case is excluded from both the numerator and the denominator.

Question 1093: What is the formula for the annual growth rate?

A. Crude birth rate minus crude death rate (Correct Answer)
B. Crude death rate minus crude birth rate
C. (Crude birth rate - crude death rate) * 100 / Crude birth rate
D. (Crude birth rate - crude death rate) * 100 / Mid-year population

Explanation: ### Explanation **Concept Overview** The **Annual Growth Rate** (also known as the Natural Increase Rate) represents the pace at which a population expands due to the balance of births and deaths. In demography, it is fundamentally the difference between the inflow (births) and the outflow (deaths) within a population over a year. **Why Option A is Correct** The formula for the **Natural Increase Rate** is: $$\text{Crude Birth Rate (CBR)} - \text{Crude Death Rate (CDR)}$$ Since both CBR and CDR are expressed "per 1000 mid-year population," the resulting value is also per 1000. To express this as a **percentage (%) annual growth rate**, the result is divided by 10 (e.g., if CBR is 20 and CDR is 8, the growth rate is 12 per 1000, or 1.2%). **Analysis of Incorrect Options** * **Option B:** This would yield a negative value in growing populations; it represents the rate of natural decrease. * **Option C:** This is a mathematically incorrect ratio that does not represent any standard demographic indicator. * **Option D:** This formula is redundant. Since CBR and CDR are already calculated using the mid-year population as the denominator, dividing by it again is mathematically incorrect for calculating a rate. **High-Yield Pearls for NEET-PG** * **Demographic Equation:** Total Growth = (Births - Deaths) + (In-migration - Out-migration). However, for "Natural Increase," migration is excluded. * **Vital Statistics:** In India, these figures are primarily obtained from the **Sample Registration System (SRS)**. * **Demographic Transition:** India is currently in **Stage 3** (Late Expanding), characterized by a falling birth rate and a rapidly declining death rate. * **Rule of 70:** To calculate the **doubling time** of a population, divide 70 by the annual growth rate (in %).

Question 1094: Which of the following is NOT a distinct feature of a case-control study method?

A. Both exposure and outcome have occurred before the start of the study.
B. The unit of study is a group rather than an individual. (Correct Answer)
C. The study proceeds backward from effect to cause.
D. It uses a control or comparison group to support or refute an inference.

Explanation: **Explanation** In epidemiology, a **Case-Control Study** is an observational, analytical study used to determine the association between an exposure and an outcome. **Why Option B is the correct answer:** The unit of study in a case-control study is the **individual**. Researchers identify individuals with the disease (cases) and individuals without the disease (controls) to compare their past exposures. If the unit of study were a **group or population**, it would be classified as an **Ecological Study**. This is a common "trap" question in NEET-PG regarding levels of organization in study designs. **Analysis of other options:** * **Option A:** This is a hallmark of case-control studies. They are **retrospective**; both the exposure and the outcome have already occurred by the time the investigator begins the study. * **Option C:** Case-control studies proceed from **"Effect to Cause."** You start with the effect (the disease) and look backward in time to find the cause (the risk factor/exposure). * **Option D:** The presence of a **comparison group** (controls) is what makes this an "analytical" study rather than a "descriptive" one. Controls provide the baseline frequency of exposure to support or refute the statistical association. **High-Yield Clinical Pearls for NEET-PG:** * **Measure of Association:** Case-control studies use the **Odds Ratio (OR)**. They cannot calculate Incidence or Relative Risk (RR). * **Best for:** Rare diseases or diseases with long latent periods. * **Main Bias:** **Recall Bias** is the most common disadvantage, as cases may remember past exposures more vividly than controls. * **Starting Point:** Always starts with the **Disease**.

Question 1095: All of the following are true regarding a confounding factor EXCEPT:

A. It is associated with exposure under investigation
B. It is distributed equally in study and control groups (Correct Answer)
C. It is associated both with exposure and disease
D. It is removed by matching in case control study

Explanation: ### Explanation A **confounding factor** is a "hidden" variable that distorts the true relationship between an exposure and an outcome. To be a confounder, a variable must meet three criteria: it must be a risk factor for the disease, it must be associated with the exposure, and it must not be an intermediate step in the causal pathway. **Why Option B is the Correct Answer (The Exception):** By definition, a confounder is **unequally distributed** between the study and control groups. If a factor were distributed equally, its effect would cancel out across both groups, and it would no longer distort the association being studied. Therefore, the goal of many study designs (like randomization) is to achieve equal distribution to *eliminate* confounding. **Analysis of Other Options:** * **Option A & C:** These are the fundamental requirements for a confounder. For example, in a study looking at coffee drinking (exposure) and lung cancer (outcome), **smoking** is a confounder because it is associated with coffee drinking (exposure) and is an independent risk factor for lung cancer (outcome). * **Option D:** Matching is a popular method used at the **design stage** of a case-control study to ensure that the cases and controls are identical regarding potential confounders (like age or sex), thereby removing their influence. **NEET-PG High-Yield Pearls:** * **Methods to control confounding at the Design Stage:** Randomization (best method), Matching, and Restriction. * **Methods to control confounding at the Analysis Stage:** Stratification and Multivariate Analysis (e.g., Logistic Regression). * **Randomization** is unique because it controls for both **known and unknown** confounders. * A confounder must **not** be an intermediate link (e.g., in Alcohol $\rightarrow$ Cirrhosis $\rightarrow$ Death, Cirrhosis is a mediator, not a confounder).

Question 1096: Which criterion is most difficult to establish when determining the causal association in the etiology of a disease?

A. Temporality
B. Strength of association
C. Specificity of association (Correct Answer)
D. Biological plausibility

Explanation: ### Explanation The question refers to **Bradford Hill’s Criteria for Causation**, a framework used to determine if an observed association is truly causal. **Why "Specificity of Association" is the correct answer:** Specificity implies that a single cause leads to a single effect (one-to-one relationship). In modern medicine, this is the **most difficult criterion to establish** because most diseases are **multifactorial** (e.g., Ischemic Heart Disease is caused by smoking, hypertension, and genetics) and most exposures cause **multiple effects** (e.g., smoking causes lung cancer, bladder cancer, and stroke). While its presence strongly supports causation, its absence does not rule it out, making it the "weakest" and hardest to satisfy in chronic disease epidemiology. **Analysis of Incorrect Options:** * **Temporality (A):** This is the **most essential/crucial** criterion. It states the cause must precede the effect. While sometimes difficult to prove in cross-sectional studies, it is conceptually straightforward and non-negotiable for causation. * **Strength of Association (B):** Measured by Relative Risk (RR) or Odds Ratio (OR). A high RR (e.g., 20.0 for smoking and lung cancer) makes the association easier to establish, not harder. * **Biological Plausibility (C):** This refers to whether the association agrees with current biological and medical knowledge. While it depends on the state of science, it is generally easier to hypothesize a mechanism than to prove a one-to-one specific link. **High-Yield Pearls for NEET-PG:** * **Most Important Criterion:** Temporality (The only "sine qua non"). * **Best Study Design for Temporality:** Prospective Cohort Study. * **Weakest/Hardest to Prove:** Specificity (due to the "Web of Causation"). * **Dose-Response Relationship:** Also known as the Biological Gradient (more exposure = more disease).

Question 1097: Which statement is FALSE regarding a cohort study?

A. Incidence can be measured
B. Used to study chronic diseases
C. Expensive
D. Always prospective (Correct Answer)

Explanation: In a cohort study, the investigator selects a group of individuals (the cohort) based on their exposure status and follows them over time to observe the development of an outcome. **Explanation of the Correct Answer (D):** The statement "Always prospective" is false because cohort studies can be classified into three types based on the timing of the data collection: 1. **Prospective Cohort:** The outcome has not occurred when the study begins; the cohort is followed into the future. 2. **Retrospective (Historical) Cohort:** Both the exposure and the outcome have already occurred at the start of the study. The investigator uses past records (e.g., medical files) to reconstruct the cohort's journey from exposure to outcome. 3. **Ambispective Cohort:** A combination where data is collected from past records and the cohort continues to be followed into the future. **Analysis of Other Options:** * **A. Incidence can be measured:** This is **true**. Since cohort studies follow "at-risk" individuals over time, they are the gold standard for calculating the **Incidence Rate** and **Relative Risk (RR)**. * **B. Used to study chronic diseases:** This is **true**. Cohort studies are ideal for studying long-term effects and chronic conditions (e.g., the Framingham Heart Study), provided the disease is not extremely rare. * **C. Expensive:** This is **true**. Due to the large sample sizes required and the long duration of follow-up, cohort studies are significantly more expensive and time-consuming than case-control studies. **High-Yield NEET-PG Pearls:** * **Direction of study:** Cohort studies move from **Cause to Effect** (Forward-looking). * **Best for:** Rare exposures (e.g., occupational hazards). * **Key Metric:** **Attributable Risk (AR)**, which indicates the amount of disease that can be prevented if the exposure is removed. * **Main Bias:** **Attrition bias** (loss to follow-up).

Question 1098: Before starting antiretroviral therapy, NACO recommends how many sessions of counseling?

A. 1
B. 2 (Correct Answer)
C. 3
D. 4

Explanation: **Explanation:** The National AIDS Control Organization (NACO) guidelines emphasize that **treatment preparedness** is the cornerstone of long-term success in Antiretroviral Therapy (ART). **Why 2 sessions are correct:** According to NACO protocols, a minimum of **two counseling sessions** are mandatory before initiating ART. 1. **Session 1 (Initial Counseling):** Focuses on the basics of HIV, the benefits of ART, the necessity of lifelong commitment, and identifying a treatment supporter. 2. **Session 2 (Follow-up/Readiness Assessment):** Conducted to reinforce the information from the first session, assess the patient's readiness, address potential barriers to adherence (like substance abuse or mental health issues), and ensure the patient understands that 95% adherence is required for viral suppression. **Analysis of Incorrect Options:** * **Option A (1 session):** A single session is considered insufficient to ensure the patient has fully grasped the complexities of lifelong therapy and the implications of drug resistance. * **Options C & D (3 or 4 sessions):** While additional sessions may be conducted if a patient is deemed "not ready" or has complex psychosocial issues, the *standard recommendation* for a stable patient is two sessions to avoid unnecessary delays in starting treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Adherence Goal:** For ART to be effective and to prevent drug resistance, a minimum of **>95% adherence** is required. * **Treatment Supporter:** NACO recommends identifying a "Treatment Supporter" (usually a family member or friend) during these sessions to supervise drug intake. * **"Test and Treat" Policy:** Regardless of CD4 count or clinical stage, all HIV-positive individuals are now eligible for ART; however, the two-session preparedness rule still applies to ensure retention in care.

Question 1099: Which of the following characteristics is not of much importance in a screening test?

A. Low cost
B. High safety margin
C. High sensitivity
D. High specificity (Correct Answer)

Explanation: **Explanation** In epidemiology, the primary objective of a **screening test** is to detect potential disease in an apparently healthy (asymptomatic) population. Because screening is the first step in the diagnostic process, the priority is to "catch" as many cases as possible. **Why High Specificity is of "not much importance":** Specificity refers to the ability of a test to correctly identify those without the disease (True Negatives). While desirable, high specificity is not the *primary* requirement for a screening test. Screening tests are designed to be highly **sensitive** to ensure no cases are missed. A test with lower specificity will result in "False Positives," but these are acceptable in a screening phase because they will be ruled out later by a more expensive, invasive, and highly specific **diagnostic test**. **Analysis of Incorrect Options:** * **Low Cost (A):** Screening is applied to large, asymptomatic populations. For a program to be viable and sustainable at a public health level, the test must be inexpensive. * **High Safety Margin (B):** Since the individuals being tested are currently healthy, the test must be non-invasive and safe. High risk or painful procedures lead to poor compliance. * **High Sensitivity (C):** This is the most critical attribute. High sensitivity ensures a low "False Negative" rate, fulfilling the goal of early detection and preventing the spread of disease or progression to advanced stages. **High-Yield Clinical Pearls for NEET-PG:** * **Screening Test:** High Sensitivity, High Predictive Value Negative (to "rule out" disease). * **Diagnostic Test:** High Specificity, High Predictive Value Positive (to "rule in" disease). * **Iceberg Phenomenon:** Screening is used to uncover the "submerged portion" (unmet need/asymptomatic cases) of the iceberg of disease. * **Lead Time:** The period between early detection by screening and the time of usual clinical diagnosis.

Question 1100: Which of the following is true regarding the duration of treatment for extensively drug-resistant tuberculosis (XDR-TB)?

A. Total duration 24-30 months (Correct Answer)
B. Intensive phase - 6 to 9 months
C. Continuation phase - 15 months
D. All of the above

Explanation: **Explanation:** The treatment of **Extensively Drug-Resistant Tuberculosis (XDR-TB)** is significantly more complex and prolonged than drug-susceptible TB due to the high level of resistance (resistance to Isoniazid, Rifampicin, any Fluoroquinolone, and at least one second-line injectable). **1. Why Option A is Correct:** According to the Programmatic Management of Drug-Resistant TB (PMDT) guidelines in India (RNTCP/NTEP), the conventional regimen for XDR-TB involves a **total duration of 24 to 30 months**. This extended period is necessary to ensure the complete eradication of highly resistant bacilli and to prevent relapse. **2. Why Options B and C are Incorrect:** * **Intensive Phase (IP):** For XDR-TB, the IP typically lasts for **6 to 12 months**. Option B (6-9 months) is the standard for MDR-TB, not specifically the upper limit for XDR-TB. * **Continuation Phase (CP):** The CP for XDR-TB lasts for **18 months**. Option C (15 months) is incorrect as it underestimates the required duration for sterilization. * Since B and C are technically inaccurate based on the specific XDR-TB protocol, "All of the above" is incorrect. **High-Yield Clinical Pearls for NEET-PG:** * **Definition Change (WHO 2021):** XDR-TB is now defined as MDR-TB plus resistance to any fluoroquinolone AND at least one additional Group A drug (Bedaquiline or Linezolid). * **Newer Regimen:** The **BPaL/BPaLM** regimen (Bedaquiline, Pretomanid, Linezolid, +/- Moxifloxacin) is a shorter 6-month all-oral regimen now being prioritized by the WHO for MDR/XDR-TB. * **Site of Treatment:** XDR-TB patients are ideally managed at Nodal DR-TB Centers. * **Monitoring:** Monthly sputum culture is the gold standard for monitoring XDR-TB treatment response.

Practice by Chapter

Principles of Epidemiology

Practice Questions

Measures of Disease Frequency

Practice Questions

Epidemiological Study Designs

Practice Questions

Descriptive Epidemiology

Practice Questions

Analytical Epidemiology

Practice Questions

Experimental Epidemiology

Practice Questions

Screening for Disease

Practice Questions

Surveillance Systems

Practice Questions

Investigation of an Epidemic

Practice Questions

Association and Causation

Practice Questions

Modern Epidemiological Methods

Practice Questions

Critical Appraisal of Epidemiological Studies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free